MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
Salarius Pharmaceuticals Operating Income 2011-2026 | SLRX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Salarius Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -12.6 M | -5.73 M | -12.9 M | -31.8 M | -12.8 M | -7.79 M | -8.27 M | -1.68 M | -34.7 M | -39.9 M | -29.2 M | -8.03 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.68 M | -39.9 M | -17.1 M |
Quarterly Operating Income Salarius Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -895 K | -966 K | -1.72 M | - | -1.01 M | -1.47 M | -1.77 M | - | -2.53 M | -3.97 M | -5.42 M | - | -14.5 M | -4.76 M | -6.12 M | - | -3.75 M | -3.12 M | -1.8 M | - | -1.76 M | -1.9 M | -2.37 M | - | -3.76 M | -912 K | -1.53 M | -2.02 M | -314 K | -9.1 M | -8.28 M | -8.09 M | -9.41 M | -8.88 M | -8.35 M | -7.98 M | -10.7 M | -11.5 M | -9.7 M | - | -8.17 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -314 K | -14.5 M | -4.96 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Amgen
AMGN
|
9.08 B | $ 350.13 | 2.98 % | $ 188 B |  USA |
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
394 M | $ 12.73 | 3.33 % | $ 3.99 B | USA |
 |
AlloVir
ALVR
|
-46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |
 |
argenx SE
ARGX
|
-349 M | $ 783.17 | 2.32 % | $ 25 B |  Niderland |
 |
Autolus Therapeutics plc
AUTL
|
-271 M | $ 1.48 | 8.82 % | $ 394 M |  Britain |
 |
Applied Therapeutics
APLT
|
-64.5 M | - | - | $ 8.42 M | USA |
 |
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B |  France |
 |
Arcutis Biotherapeutics
ARQT
|
-12.2 M | $ 24.57 | 5.59 % | $ 3.13 B | USA |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | France |
 |
AVROBIO
AVRO
|
10.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
1.06 B | - | - | $ 96.9 B | Britain |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | Britain |
 |
BioNTech SE
BNTX
|
15.3 B | $ 91.64 | 2.25 % | $ 27.2 B | Germany |
 |
BeiGene, Ltd.
BGNE
|
447 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Burford Capital Limited
BUR
|
242 M | $ 4.62 | 1.54 % | $ 742 M | Britain |
 |
CymaBay Therapeutics
CBAY
|
-102 M | - | - | $ 3.45 B | USA |
 |
Advaxis
ADXS
|
-36.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aytu BioScience
AYTU
|
-7.83 M | $ 2.68 | 4.28 % | $ 16.8 M | USA |
 |
Avid Bioservices
CDMO
|
-18.7 M | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
-176 M | - | - | $ 1.41 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.13 M | $ 3.05 | 0.66 % | $ 6.64 B | Israel |
 |
Cabaletta Bio
CABA
|
-172 M | $ 3.05 | -0.5 % | $ 306 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
-56.2 M | - | - | $ 169 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M |  Canada |
 |
Checkmate Pharmaceuticals
CMPI
|
-61.5 M | - | - | $ 231 M | USA |
 |
Cerus Corporation
CERS
|
-8.68 M | $ 1.93 | 4.62 % | $ 368 M | USA |
 |
AgeX Therapeutics
AGE
|
-24 M | - | -10.17 % | $ 12.2 K | USA |
 |
Concert Pharmaceuticals
CNCE
|
-77.5 M | - | - | $ 401 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
-79.8 M | - | - | $ 1.2 B | USA |
 |
AIkido Pharma
AIKI
|
-55.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-8.43 M | - | -4.36 % | $ 27 M | USA |
 |
Cellectar Biosciences
CLRB
|
-23 M | $ 2.83 | 2.91 % | $ 7.38 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-211 M | - | - | $ 2.18 B | USA |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
-4.12 M | - | - | $ 2.02 B | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Coherus BioSciences
CHRS
|
-181 M | $ 1.73 | 3.59 % | $ 203 M | USA |